Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Advanced manufacturing of drug substances by co-processing with excipients through heteronucleation in a milifluidic device

Descrizione del progetto

Rivoluzionare la produzione farmaceutica in continuo

L’industria farmaceutica sta registrando una domanda crescente e prevede periodi di aumento caotico a causa di malattie e pandemie derivanti dai cambiamenti climatici. Nonostante gli sforzi per promuovere la produzione in continuo, che promette una produzione di farmaci più economica, sostenibile, adattabile e veloce, le scarse proprietà meccaniche di molte sostanze le rendono inadatte a questo processo. Il progetto ManCoProc, sostenuto dal programma di azioni Marie Skłodowska-Curie (MSCA), cerca di affrontare questa sfida sviluppando una piattaforma universale di co-elaborazione farmaco-eccipiente che sfrutta le tecniche di cristallizzazione e co-precipitazione per superare i limiti posti dalle scarse proprietà meccaniche di numerosi farmaci. Il progetto utilizzerà tecnologie e tecniche all’avanguardia per analizzare e ottimizzare questo processo innovativo.

Obiettivo

Pharmaceutical industry is starting to adopt the approach of continuous manufacturing, with as few unit operations as possible, to deliver drug products in a faster, robust, cheaper and sustainable way.
Poor mechanical properties of many drug substances are a hindrance to this, making them unsuitable for direct compression into tablets without additional operations. This challenge can be solved by co-processing: joining the particles of such drugs to the particles of inactive substances known as excipients (e.g. lactose), normally used for tablets production.
The aim of this project is to develop a universal drug-excipient co-processing (CP) platform based on surface crystallization or co-precipitation. A CP method in a milifluidic device will be optimised with a range of drugs with differing physicochemical properties. The relationships between them, as well as excipient properties, parameters of the method and structural and functional characteristics of the obtained composites will be thoroughly investigated. To this end, cutting edge techniques will be employed to analyse particle size, morphology, dissolution and mechanical behaviour. To demonstrate improved manufacturability, the prototype CP material will be used for direct compression, and the tablets quality will be evaluated according to European Pharmacopeia requirements.
The project will enable the researcher to achieve professional maturity in the field of particle engineering, allowing to employ her skills both in academia and in pharmaceutical industry. The results of the research will have commercialisation value, being of interest to companies as a potential new platform in (pre)formulation portfolio. The project will contribute to the body of evidence informing the decisions of regulators on pharmaceutical co-processing. In the long term, such impact should advance the transformation towards continuous manufacturing of affordable, available and sustainable drug products.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2023-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE
Contributo netto dell'UE
€ 119 097,32
Indirizzo
TECHNICKA 5
166 28 PRAHA
Cechia
Regione
Česko Praha Hlavní město Praha
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partner (1)